Findings represent first validation of any gene expression biomarker for intermediate-risk patients using data from a randomized phase 3 clinical trial Prostate cancer deemed “intermediate risk” by ...

- VANDAAM study findings confirm test predicts aggressive prostate cancer in African American men - Additional Decipher GC findings to be presented at ASCO include new data from a retrospective ...

WASHINGTON — Combining short-term androgen deprivation therapy (ADT) with high-dose radiotherapy improves disease-free survival in men with intermediate-risk prostate cancer compared with high-dose ...

The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT). (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that eight abstracts featuring data derived from testing with ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the launch of its Decipher Prostate Metastatic Genomic ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond 9 to 12 months of ADT. HealthDay News — Increasing duration of androgen deprivation therapy (ADT) ...

Source: Getty Images High-dose radiotherapy “needs the addition of short-term ADT to improve outcomes in intermediate- and high-risk localized prostate cancer,” according to Nicolas Demogeot, MD. The ...

THURSDAY, Dec. 4, 2025 (HealthDay News) -- Increasing duration of androgen deprivation therapy (ADT) is beneficial for some men with prostate cancer, while those with lower risk cancer may not need ...